Human melanoma cell line ilg which secretes recombinant granulocytic-macrophagal colony-stimulating factor

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line ILG has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The ILG cell line is deposited in the Special collection of cell cultures of vertebrates of the Russian collection of cell cultures under number RKKK (P) 697D. All cells of the ILG line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

 

The technical field of the present invention

The invention relates to the field of biology and medicine, in particular the production of genetically modified cell lines used for immunotherapy and immunization in patients with malignant tumors.

The prior art of the present invention

Activation of the immune system can stop the proliferation micrometastatic foci of tumor cells persist in the body of cancer patients after cytoreductive interventions [1]. Moreover, using immunotherapy is possible to achieve reduction and even disappearance of relatively large metastases and primary tumor sites in those cases when other treatments are not possible. The literature describes a case of regression of tumor size in 690 cubic centimeters in the adoptive transfer of antitumor T lymphocytes [2]. The observed cases of achieving a complete remission of cancer after antitumor vaccination with whole cell genetically engineered vaccines [3].

There are two different ways to generate protective immunity - active and passive. Active immunization or vaccination is called the stimulation of the formation of antigen-specific antibodies or T-cells using rst the value of the target antigen in combination with means, inducing the immune response. In contrast, passive immunization involves moving a formed in the other body effectors of the immune response - antibodies or lymphocytes. As an active immunotherapy, adoptive transfer can have a pronounced antitumor activity [2].

Among the most effective forms of activating private antitumor immunity of the patient allocate whole cell tumor vaccines secreting immunomodulatory cytokines. To receive these vaccines tumor cells transferout gene constructs encoding the appropriate cytokines, inactivating gamma-irradiation and injected into the body of patients. Secretion of tumor cells cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), IL-12 promotes the formation of a strong tumor-specific immune response. Recent advances in the field of active specific immunotherapy associated with the use of vaccines on the basis of cells secreting chimeric molecule consisting of the active sites of several cytokines (e.g., GIFT, connecting the activity of GM-CSF and IL-2) [4].

Vaccination with autologous tumor cells of patients is fraught with many technical difficulties, such as the availability of the tumor for hee is oricheskogo removal, establishing a short-term cultures of tumor cells, the number of received cells, the efficiency of delivery of a therapeutic gene and the level of its expression. In this regard, D. Pardoll proposed to use for vaccination allogeneic stable transfetsirovannyh cells with a high level of expression of GM-CSF [1]. The idea was supported by established fact cross-presentation of tumor antigens by dendritic cells of the patient, as well as the fact that many of immunological relevant tumor antigens were common to tumors of the same histological origin, and for tumors of various origins.

Despite the fact that the approach sharpens the question of the adequacy of vaccine antigens and the tumor, clinical trials have shown that the effectiveness of allogeneic vaccination is not inferior to the results obtained using autologous cells [5]. Moreover, the effect of allogeneic stimulation and the opportunity to enter a really large number of cells from patients with minor tumor size, giving the most significant results in the entire history of active specific immunotherapy of tumors [3].

Some time after the introduction of the vaccine, which represents an inactivated genetically modified tumor cells, with cretinous GM-CSF, in the injection area creates a concentration gradient of the cytokine. GM-CSF induces positive chemotaxis and activation of monocytes and granulocytes in the blood and tissue macrophages. Immunohistochemical study of the introduction of the vaccine in 24-48 hours after injection reveals infiltration by granulocytes and cells of the monocytic/macrophage series [6]. Under the action of GM-CSF increases the production of IL-1 and tumor necrosis factor (TNF) by macrophages and develops local inflammatory response in which macrophages, granulocytes, and additionally engage in the field of injection of NK - and NKT-cells gradually destroy the entered cell vaccine.

A key factor contributing to the immunogenicity of GM-CSF-secreting vaccines is the ability of this cytokine to induce differentiation of early precursors in the direction of the most effective professional antigen presenting cells - dendritic cells [7]. It is shown that this process occurs in the injection area secreting GM-CSF tumor cells, if you enter cells produce a sufficient number of cytokine - not less than 36 ng to 106cells for 24 hours [3]. It is essential that the maximum concentration of GM-CSF is created in the immediate vicinity of the injection of genetically modified cells. In Mature dendriticum (DC) differentiate their predecessors, localized near the cell vaccines and, therefore, faguoqitirute the decay products of tumor cells. The study of sequential biopsy specimens designated for the vaccine shows that by 3-4 days among infiltrating the area of the cells there is a significant amount of DC expressing costimulation molecules, and to 5 days these cells are found in the regional lymph nodes [9].

Further stages of the immune response is the presentation of antigenic peptides from tumor antigens in the context of the molecules of the major histocompatibility complex (MHC) class II naive CD4+T-helper cells (Th0)that stimulates their differentiation into Mature T-helper type 1 and 2. As a result, the cross-presentation of tumor antigens by dendritic cells occurs in priming naive CD8+T-cells that stimulates their differentiation into functionally active cytotoxic T-lymphocytes. CD4+T-helpers of the first type contribute to the formation of clones of CD8+CTL. In addition, it was found that metastases vaccinated GM-CSF-secreting vaccines patients are abundantly infiltrated by lymphocytes, the majority (96%) which is a CD4+Th1cells, effectors hypersensitivity reactions slow (tuberculin) type[3, 10, 11].

Another subpo ulacia T-lymphocytes - CD8+CTL - carry out the destruction of tumor cells and endothelial cells of tumor stroma in the case of the recognition of cross-prezentirani their tumor antigens. For the implementation of the antitumor effect the necessary secretion of interferon-gamma [12]. Under the action of interferon-gamma increases the expression of MHC-I on tumor cells and tumor stroma, which increases the efficiency of recognition and power activating signal and, thereby, allows T-cells to carry out the induction of apoptosis in the target cell: secreted by cytotoxic cells (CTL) perforin forms pores in the cell membrane of the target, through which tumor cells penetrate Grasim In, which triggers a cascade of programmed cell death. Very likely, in addition to this mechanism, there are other ways of destroying tumor cells like T-lymphocytes and other cells. In particular, the ability to destroy cells of various tumors exhibit NK - and NKT-cells and activated by various factors (including GM-CSF) granulocytes and macrophages.

In several clinical trials have shown that the use of GM-CSF-secreting vaccines affect the level of this cytokine in the serum of patients that stimulates the proliferation of early myeloid precursors and, in particular, the precursors of dendritic CL is current, that may be essential for the antitumor effect of immunization [5].

Whole cell tumor vaccines based on GM-CSF may represent transtorno transfetsirovannyh autologous cells of the patient, obtained after surgical removal of the tumor, or allogeneic tumor cells cultured in vitro cell cultures secreting GM-CSF in the transient or stable transfection. Between these two approaches there are significant differences in immunological effects, and in the technology of preparation of the vaccine.

Autologous vaccination is always preceded by a surgical procedure is necessary in order to obtain tumor tissue. From distant tumor sites get monoclonal suspension, which is cultivated in vitro in the form of short-term cell culture. The cells transferout gene construct that encodes GM-CSF, inactivate by ionizing irradiation and injected patients; some cells preserved by freezing for subsequent vaccinations. The duration of the process of preparation of the vaccine varies from 20 days to three months [8].

A significant drawback of autologous vaccination is the need to do all these manipulations individually for each patient. This leads ktomu, that method is extremely difficult to standardize, and dramatically increases the cost of vaccination. It is also clear that the autologous vaccine therapy can be performed only for those patients, the tumor which are available for surgical resection.

A limitation of the approach is the number obtained from the patient's cells. As a rule, a significant number of cells could be obtained from patients with large and multiple tumor sites. Such patients are often in poor condition, have a marked secondary immunosuppression and as a consequence poorly respond to immunotherapy. In contrast, patients with a low degree of progression and neoplastic process that has a high chance of successful vaccination, in most cases, have tumors of smaller size, of which you cannot obtain a sufficient number of cells.

Clinical trials of autologous GM-CSF-secreting vaccines showed that the effectiveness of vaccine therapy depends not only on the number of input cells, but also on the amount of secreted their cytokine [5]. The productivity of the cells of the vaccine are usually estimated by the number of GM-CSF secreted per day one million cells in vitro. Accordingly, under conditions of transient transfection this productivity depends both on the proportion Transvision is the R cells, and the amount of cytokine produced by each cell. Although the currently used vectors based on adeno-associated viruses can achieve high productivity, maintaining a certain dependence of the vaccine therapy as to the efficiency of transfection and the ability of individual cells to produce sufficient amount of cytokine[5, 9, 13].

A significant factor affecting the effectiveness of autologous vaccine therapy, is the period of time required for preparation of the vaccine. It is known that immediately after removal of the primary tumor in the body of the patient changes, resulting in stimulation of growth of distant metastases [14]. In the same period disappears or reduces the number of factors that have contributed to the suppression of the antitumor immune response, and formed the conditions for the development of effective antitumor immunity. When immunization is carried out in the first days after the removal of the tumor, its efficiency becomes significantly higher. On the contrary, vaccine therapy initiated after 15 or more days after surgical rehabilitation, is less effective due to the fact that remaining in the body, tumor cells acquire the necessary time to adapt, to form the stroma and eff is active to resist the immune response [5].

At the same time, the vaccine therapy with autologous tumor cells has a significant advantage due to the maximum immunological match antigenic components of the vaccine and the original tumor. One of the most important components of the effector part of the immune response to the tumor is in the cytotoxic activity of CD8+T-lymphocytes that are specific for certain tumor antigens. A necessary condition for the implementation of the cytotoxic activity is the expression in cells of a tumor specific antigen and its presentation in the context of MHC molecules of class I. At the same time, to generate CTL clones with antitumor activity requires the introduction of the same antigen in the composition of vaccinereports. It is established that tumor cells contain, as a rule, not one antigen, and some of their set of several dozen known antigens that are unique to each tumor [15]. In terms of experimental studies have shown that the closer the antigenic composition of vaccines and tumor, the greater the effect can be achieved using whole cell vaccine therapy. It is also important that the impact on the formation and the efficiency of the immune response renders not only the presence or absence of the specific antigen in the cells of the vaccine, but the ratio of the number of separate antigen is. Despite the fact that the antigenic composition of the surgically removed tumor and its remaining in the body metastases may vary, vaccines, created on the basis of autologous cells are maximally close antigenic composition to the tumor cells of the patient [16].

Unlike autologous allogeneic vaccines vaccines are modified cells previously obtained from other patients and some time in vitro. As a rule, it is a stable, homogeneous, well-proliferating cell lines with a high content of immunogenic tumor-associated antigens that are common to many types of tumors [17]. Selected for preparation of the vaccine line transferout gene constructs encoding GM-CSF, and then hold breeding and cloning, which gives a stable clone is a variant of the original cell line, all cells which secrete a certain amount of the cytokine. With the help of further modifications (re-transfection, sublimirovanny, amplification) may receive a stable variant cell lines with very high productivity. Thus obtained clones form the basis of allogeneic vaccines: the cells of one such clone, multiple modifications to the same source line, or even a combination of several different clones of lines to grow is up in the required quantity, inactivating gamma-irradiation and administered to patients.

In allogeneic vaccines are missing almost all manufacturing defects with autologous vaccination. All patients included in the program of biotherapy, enter the same preparation in advance is characterized by the level of productivity, the expression of tumor-associated antigens, immunophenotype etc. Allogeneic vaccines do not depend on the results of surgical treatment and can be applied in patients without surgical intervention. It is also important and something that started the vaccine therapy is possible in the first days after surgery, or even before it. When using allogeneic vaccination there is no technical limit to the number of input cells, which allows the use of large quantities of cells (500 million cells per vaccination), producing significant amounts of GM-CSF, and thereby to achieve the best results possible. An important factor is that allogeneic vaccine significantly cheaper autologous and that they receive after the development of the original clones is a much less labor-intensive process.

However, the introduction of alien patients for them allogeneic cells requires a careful selection of the varying composition of the vaccine for each patient. Irrelevant for autologous vaccine is AI, the question of compatibility antigenic components of the vaccine and tumor becomes crucial. In model systems have shown that it is sufficient to immunize experimental animals against one expressed in the tumor antigens to cause rejection of the entire tumor [18]. However, transformed by viral oncogenes murine cell line, as well as b-cell lymphomas are rare cases favorable match most critical for immunotherapy properties of tumor antigens, such as absolute specificity for the tumor and the need for antigen for the survival of tumor cells [19]. In the vast majority of other tumors can form variants of tumor cells escaping from the attack of T-lymphocytes and antibodies [20]. Losing the antigen or necessary for its presentation option MTL tumor subclones become immune to immune response, continue to grow and progress in the body and eventually lead to his death.

The formulation of tumor cells lose the expression of the tumor antigen is the result of random genetic events resulting in damage or disable the corresponding gene. Because these events are random, the probability of simultaneous loss of two or more antigens in the same cell is significantly lower than the probability of losing one antigen. Accordingly what about, simultaneous immunization with multiple antigens expressed in tumor, may be more effective than immunization against one. This expectation is confirmed by the results of clinical trials [21]. Therefore, it is highly likely that when allogeneic vaccination positive results can be expected only when the spectrum of tumor antigens expressed by cells of the vaccine, widely overlaps with the spectrum of tumor antigen specific patient's tumor. Because of the antigenic components of the vaccine are known in advance, it is advisable before starting immunotherapy to determine the antigenic profile of the patient's tumor. In addition, you must determine which of the variants of the MHC molecules are borne by the patient, because the presentation of a number of tumor-associated antigens (and, consequently, the possibility of an adaptive immune response to them) is unique for a limited number of options histocompatibility molecules.

A possible scenario when the tumor contains antigenic proteins, the products of which cannot be represented in the MTL of the patient, up to the present moment does not have a solution. Some researchers believe that it is advisable, however, immunisation of such antigens in the calculation that can be characterized variants of the anti-Christ. Jena, can pretentious in his MNF, or that even if it is not presented in the context of the molecules of the major histocompatibility antigen may be targeted by the immune response [22]. At the same time, some authors believe that the introduction of these antigens in a vaccine composition will adversely affect the final result due to the fact that at a critical time of vaccination, the immune system becomes too "loaded" with regard to irrelevant targets. This view is confirmed by the examples of infectious immunology: with most viral infections can potentially shape the immune response to hundreds of different epitopes of viral antigens, however, are practically immune response is only a few so-called immunodominant epitopes [23, 24]. Response to immunodominant epitopes may be ineffective and even harmful, because domination is not possible to generate an immune response to other antigens, more effective for protection against the pathogen, but less convenient for immune recognition [25].

Definition immunophenotype patients loci leukocyte antigens of human histocompatibility (HLA-A and HLA-B is also required in order to assess the degree of compatibility MTL patient cells and vaccines. As in the case of an antigenic composition, this is the first time there is no consensus, what options histocompatibility molecules in cells vaccine optimal for the introduction of certain patients. In General, there are three options allogeneic vaccines: 1) the maximum (or full) line input cells HLA phenotype of the patient, 2) the lack of conformity (low match) MTL patient and cell vaccine, or 3) the use of allogeneic tumor cell vaccines, not expressing the surface antigens of histocompatibility.

When used as a vaccine tumor cells with a high degree of compatibility allogeneic vaccination approaches for immunological effects to vaccination own tumor cells of the patient: the early introduction of the vaccine increases the residence time of cells in the body of vaccinated patients, as it does not transplant rejection, developing in the cells of the "other" HLA phenotype [26]. However, this effect remains only in the first few injections of the vaccine, and with continued immunization of input cells, in contrast, quickly destroyed because Express antigens in the context of "their" MNS, which can be recognized formed after the first vaccination cytotoxic T-lymphocytes. Another aspect of this vaccine is the fact that many of variantimage histocompatibility class I serve as ligands inhibitory receptors of cytotoxic lymphocytes [20]. The presence of these ligands on tumor cells, as well as vaccines inhibits the cytotoxic activity of CTL, γδ-lymphocytes, NK - and NKT-cells, which may adversely affect the formation and implementation of the immune response [27]. The presence of lymphocytes of the patient corresponding receptors is an important argument in favour of using such a patient allogeneic vaccines, not bearing the appropriate HLA.

Vaccines, bearing molecules HLA, non-native haplotype, can lead to the introduction of cells develop reactions transplant rejection, mediated CD8+T-lymphocytes, NK - and NKT-cells. With the development of alloimmunity activated cytotoxic cells that can recognize their own lack of histocompatibility molecules (NK-cells), or recognize the structure of foreign MHC molecules as a gross distortion of their own (T-lymphocytes and NKT cells). The result of the activation of effectors protivoinfektsionnogo immunity is accelerated rejection of the cells of the vaccine in the reactivation, resulting in 3-4 immunization of allogeneic cells completely eliminated within the first few days [28]. At the same time, allogeneic stimulation can have a positive effect on the antitumor immune response through stimulation on the freely rare pool of cytotoxic lymphocytes with potentially automativcally activity. These lymphocytes are atypical for most T-lymphocytes T-cell receptor with differences in complementarity determining region (CDR) 2 and 1, which allows us to recognize as allogeneic MHC and modified molecules of the major histocompatibility tumor cells [29].

Another significant feature of alloimmunization is the property of allogeneic cells to induce polyclonal activation of T-lymphocytes, including inhibited by mechanisms of peripheral tolerance. Probably not physiologically high frequency of meetings of T-lymphocytes from allogeneic histocompatibility molecules is not dependent costimulation activate some part of T-cells without taking into account the specificity of their T-cell receptor (TCR). Among the respondents on alloantigen lymphocytes can be and CD4+and CD8+T cells specific for tumor antigens. Due to this stimulation of tumor-specific lymphocytes become activated phenotype and are able in certain circumstances to make several divisions, thereby increasing the total number of original rare clones. Thus, allogeneic polyclonal stimulation can produce antitumor T-lymphocytes to specific response to tumor antigens, which is practically impossible when using purely the monoclone the school, specific stimulation.

One of the interesting aspects of allogeneic vaccine therapy is the ability to use tumor cells expressing molecules major histocompatibility complex class II. In a healthy organism the expression of HLA-DR, DQ and DP is limited to the population of professional antigen presenting cells (APC) (b-lymphocytes, macrophages and DC) and activated T-lymphocytes, endothelial and epithelial cells, fibroblasts and other parts of the tumor lines derived from patients with metastatic melanoma, also detected the expression of HLA-DR, the biological meaning of which is not clear. It is shown that the signals generated by the binding of HLA-DR with TCR, activate anti-apoptotic cascades that may promote the survival of tumor cells. In addition, the presence of MHC class II on tumor cell can have a value for the tolerance of the organism to tumor antigens, as presented epitopes (in the context of MHC class II) is not on ARS, and on tumor cells that do not have molecules that provide co-stimulating signals. According to modern concepts, premirovanii such tumor cells naive T lymphocytes in the absence of signal 2 (costimulation) and cytokine necessary support can lead to apoptosis of T lymphocytes and those who amym to eliminate T-cells, specific to tumor antigens.

The application in allogeneic tumor cell vaccines expressing variants of MHC class II, coinciding with the haplotype of the patient, and not expressing the molecules of the family V7, can lead to the formation of tolerance to tumor antigens in response to the introduction of the vaccine [30]. In addition, significantly increases the risk of development of autoimmune complications and other immunopathy, because the conditions for stimulation of specific subpopulations of CD8+cells that can recognize MHC class II [31].

Another option vaccines based on allogeneic vaccine cells is the use of tumor lines, lost surface expression of molecules of the major histocompatibility complex as a result of various disorders. Many of these lines with the introduction into the organism of experimental animals relatively quickly destroyed by NK cells, which are able to implement cytotoxicity in the absence of an inhibiting signal from the molecules of MHC I on the target cell [32]. According to various estimates stay viable cells of the vaccine, not expressing HLA molecules in the body of the patient, is from 3 to 6 days, which is, in General, sufficient to make the necessary immunostimulation. In addition, the term of such vaccine cleto is in the patient's body almost does not change with repeated vaccinations. It is not clear whether there are any immunological peculiarities of the action of allogeneic vaccines on the basis of cells, not expressing antigens of histocompatibility. On the one hand, cells that were not exposed to the TCR-MHC-dependent cytotoxicity, represent a more stable source paracrine GM-CSF, suggesting greater efficacy of the vaccine when multiple immunizations. In addition, the lack of HLA molecules relieves the inhibitory effect of tumor cells to the cytotoxicity of NK-cells and creates conditions for the involvement of these cells in the inductive phase of the immune response. On the other hand, the mere receipt of such cell lines from metastatic aggressive tumors testifies to the fact that the MNF-negative lines are formed specific mechanisms of avoidance cytotoxic activity as NK-cells and T-lymphocytes. Many aspects of the use of vaccines on the basis of such cells require further investigation, especially considering the fact that the factors responsible for the stability of the MHC-negative tumor cells to the action of NK-cells, can have a negative effect on the formation of an immune response.

The disclosure of the present invention

The essence of the present invention is to provide a new unique cell line human melanoma ILG, with the ability in order to ecretariat immunoactivity cytokine - granulocyte-macrophage colony-stimulating factor. The uniqueness of this cell line is determined by using as material for genetic modification of a unique cell line human melanoma Mel IL (RF patent No. 2387577). The ability of the cell line ILG to secrete recombinant GM-CSF is achieved by genetic modification of the cells of melanoma Mel IL gene construct containing the complementary DNA of GM-CSF human (SEQ ID NO:1)embedded in a vector designed for expression in mammalian cells.

The technical result consists in obtaining lines of human melanoma cells ILG, stably transfected with the gene for GM-CSF and secreting this cytokine in the extracellular space under cultivation in vitro, as well as when using inactivated cells for administration to patients. The secretory cells ILG GM-CSF leads to activation of the immune response against tumor antigens expressed by cells of the ILG, with the introduction of inactivated cells of patients.

The aim of the present invention is an expanding collection of unique cell lines that can be used for immunotherapy of malignant tumors. This task is relevant to the modern practice of treating malignant tumors, because the range of the individual antigens is different tumors is unique at that time, as the maximum effectiveness of immunotherapy is achieved through selection for patients of a vaccine with the most complete matching set of tumor antigens in the cells of the vaccine and tumor.

Technical result achieved when using the invention lies in the possibility of using inactivated cell line human melanoma ILG for administration to patients suffering from cancer, to stimulate antitumor immunity, which gives the opportunity to increase the effectiveness of treatment and to increase life expectancy in the treatment of malignant tumors, and to immunoprophylaxis of malignant tumors.

Additional technical result achieved when using cells ILG, is that cells ILG, cultured in vitro, can be a source of biologically active GM-CSF, which can be used for culturing cells, which require the presence of GM-CSF in the culture medium. Recombinant GM-CSF man, produced by cells of the ILG, can be used as a stand-alone, high-purity protein and the composition of the culture medium or its derivatives.

The problem is solved in that the resulting new cell line human melanoma ILG, secreting recombinant GM-CSF not less than 400 ng/10 6cells for 24 hours. The obtained cell line has a stable cultural, morphological and immunological properties and has the ability to secrete recombinant granulocyte-macrophage colony-stimulating factor as a result of genetic modification. All cell lines ILG are characterized by stable secretion of GM-CSF, continued after inactivation of cells with ionizing radiation at a dose of 100 Gy, reliably preventing the proliferation of inactivating cells. Cell line ILG deposited in the special collection of cell cultures vertebrate Russian cell culture collection under the number RCCC (P) D.

The implementation of the present invention

The procedure for obtaining genetically modified human melanoma cells ILG, secreting GM-CSF

Obtaining clones

For transfection were purified using plasmid DNA gene construct, the coding sequence of the cDNA for GM-CSF, human, built-in vector designed for expression in mammalian cells, with the gene of resistance to selective antibiotic geneticin (G418) (SEQ ID NO:1).

Cell line Mel IL sown on Cup diameter 35 mm and were cultured for 24 hours to achieve a density of 16,000 cells/cm2.

After 24 hours of cultivation (after attaching and adaptation) to the cells to which alali dissolved in binding buffer transfection complex, consisting of lipid and DNA associated with enhancers. For line Mel IL used lipid and enhancer from a set Unifectin-M (Maxifectin), the amount of DNA used 1.5×106cells, was 5.6 ág. Preparation and submission transfection complex in the Cup with the cells was carried out in accordance with the manufacturer's instructions of the kit for transfection (Unifectin Group, Russia).

After 24 hours incubation with transfection mixture Wednesday in the cups were replaced with new cells and after a short adaptation perseval on cups with a diameter of 100 mm

After 24 hours incubation of the cells in culture medium were added selective antibiotic G418 (Sigma, USA) at a concentration of LD100(800 µg/ml).

After 1 week of incubation with the antibiotic (if necessary, the medium was replaced with the addition of a new portion of the antibiotic) resistant to the drug, the cells formed clones 75-150 cells in each.

Clones of cells was transferred into a 96-well plate using microdontia, to do this after removing the medium and washing the surface of the Cup on PBS clone under a microscope inflicted 10-15 ál of trypsin solution. After 30 seconds ukrepivshis cells captured by microdonation and transferred into prepared wells of 96-well plate with 200 μl of complete RPMI-1640 medium.

After 3-6 days successfully selected clones formed a monolayer, and their pen is carried in a 24-well plate. After formation of the monolayer of cells was transferred into a 6-well plate.

From 6-hole tablet supernatant was collected for analysis of concentration of GM-CSF enzyme-linked immunosorbent assay, and the cells were perseval on 4-well plate, in which the clones were frozen at -135°C.

The concentration of GM-CSF enzyme-linked immunosorbent assay (ELISA)

After forming cells transfected clones density monolayer in 6-hole tablet (1,2×106of cells per well) culture medium was completely removed from the wells, the surface of the monolayer was washed once with 2 ml sterile PBS and the wells were added to 2 ml of complete RPMI-1640 medium.

After 24 hours, samples of the supernatant from each well was collected in cryoprobes and frozen at -20°C prior to the accumulation of optimum for the production of analysis number of samples.

After collecting 40 or more samples using a commercial kit ELISA GM-CSF human production Diaclone (USA) conducted the analysis of supernatants by ELISA in the following sequence.

The supernatant samples were thawed at room temperature, was stirred on a vortex for 10 seconds and centrifuged at 13400 rpm for 30 seconds. Each well pad production reaction were added to 50 ál analytical buffer. In the pre-marked holes were added 50 μl of a hundred is Darth GM-CSF in the wells for calibration 50 ál analytical buffer in the control wells and 50 ál samples to the remaining wells. The completed tablet incubated for 2 hours at room temperature on a rotator with a speed of 111 Rev/min After 2 hours from the wells was removed liquid, each of the wells washed four times with 400 μl of wash buffer. Later in the wells was added 100 μl of secondary antibody (conjugate antibodies against hGM-CSF and Biotin), and incubated for 1 hour at room temperature on a rotator at 111 rpm After 1 hour from the wells was removed liquid, each of the wells washed four times with 400 μl of wash buffer.

Later in the wells was added 100 μl conjugated with streptavidin enzyme (HRP-streptavidin) and incubated for 30 minutes at room temperature on a rotator at 111 rpm

After 30 minutes from the wells was removed liquid, washed four times each well with 400 μl of wash buffer.

Later in the wells was added 100 μl of color-forming substrate (stabilized Chromogen TMB) and incubated for 30 minutes at room temperature in the dark on the rotator at 111 rpm

After 30 minutes, the wells were added to 100 ál of stop solution and determined the optical density on the reader LabSystem (wavelength 450 nm).

Based on these results build the calibration curve and determine the concentration of GM-CSF in samples.

In the result of the method of transfection and subsequent selection was received line ILG, producing at least 400 ng GM-CSF is secreted 1 million cells per 24 hours).

The main characteristics of the cell line ILG

Lineage cell lines:

The cell line obtained from a sample of the tumor tissue of the patient IAI, and/b 99/16486, ill in 1999, the diagnosis of disseminated melanoma skin of the abdomen. Material obtained from a sample of metastasis in soft tissue of the chest. Stable transfection performed at the Institute of gene biology, Russian Academy of Sciences in 2007.

The number of passages:

At the time of preparing passports cell line was 16 passages.

Standard culturing conditions:

Culture medium RPMI (90%), fetal calf serum 10%, containing antibiotics (penicillin with streptomycin at a concentration of 100 u/ml and 100 µg/ml, respectively).

Method of removal: 0.25% solution of trypsin and 0.02% solution of versene in a 1:1 ratio.

Cultural properties:

For growing crops, you can use the culture flasks. Vials with an area of growth 25 cm2in 5 ml of medium seeded with 1×106cells. Passage 1 every 3-4 days. Cultivation at 37°C and 5% CO2. Cells have adhesive, monololy character growth.

Karyological characteristics of strain:

The number of chromosomes in the cell from 41 to 59. The modal chromosome number of 56. Permanent markers m1, m2, m3, m4, m5, m6, m7, m8, m9.

they cell culture:

LG is characterized by the presence of polymorphic melanoma cells rounded and spindle-shaped forms and multiple multicentric educated growth zones rounded cells with hyperchromic nuclei, containing 1-2 nucleoli. The cytoplasm is relatively abundant with coloring from basophilic to light blue with a noticeable enlightenment around the nuclei. There are a few 2's and giant multinucleated cells, numerous mitoses.

Marker features:

Surface antigen expression: CD63+; NMW+; MelanA+; Tyrosinase+; HMW+; HLA-A,B,C(+); HLA-DR(-). Secrete GM-CSF person in an amount not less than 400 ng/106cells for 24 hours.

Contamination:

Bacteria and fungi in culture is not detected. Test for Mycoplasma negative.

Conditions of cryopreservation:

Cells cell line resuspending environment for freezing: nutrient medium RPMI 70%, fetal calf serum 20%, DMSO 10%. The mode of freezing: liquid nitrogen, the temperature decrease of 1°C per minute -25°C followed by rapid freezing to -70°C. Storage in liquid nitrogen at a temperature of -196°C. Defrost quickly, at 37°C. Cells diluted in 10 ml serum-free medium and precipitated by centrifugation, resuspended in 5 ml of the same medium containing 10% fetal calf serum, and transferred into a culture flask with an area of growth 25 cm2. Cell viability is assessed according to the inclusion Trypanosoma blue. Cell viability after thawing is 90%.

The list of cited sources

1. Pardoll D.M. Spinning Molecular immunology into successful immunotherapy. // Natur Reviews Immunology 2002 Vol.2, P.227-238.

2. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. // Nat Rev Immunol. 2006 Vol.6, P.383-93.

3. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'reilly S, Abrams RA, Pardoll DM, Cameron JL, Yeo CJ. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumour vaccine for pancreatic cancer: a phase I trial of safety and immune activation. // The Journal of Clinical Oncology 2001 Vol.19, P.145.

4. Stagg J, Wu JH, Bouganim N, Galipeau J. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. // Cancer Res. 2004 Vol.64, P.8795-9.

5. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. // Cytokine Growth Factor Rev. 2002 Vol.13, P.185-193.

6. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. // Nat Rev Cancer. 2004 Vol.4, P.11-22.

7. Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. // The Journal of Clinical Investigation 1990 Vol.85, P.955-61.

8. Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. // Methods. 1997 Vol.12, P.143-53.

9. Dranoff G. GM-CSF-secreting melanoma vaccines. // Oncogene. 2003 Vol.22, P.3188-92.

10. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF. The Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. // Cancer Res. 1997 Vol.57, P.1537-1546.

11. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-timulating factor using ex vivo gene transfer. // Cancer Res. 1999 Vol.59, P.5160-8.

12. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions // J. Exp. Med. 2001 Vol.194, P.1549-1559.

13. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. // Int Rev Immunol. 2006 Vol.25, P.321-52.

14. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer. 2004 Vol.90, P.2344-8.

15. Wortzel, R.D., Philipps, C., Schreiber, H. Multiple tumour-specific antigens expressed on a single tumour cell. // Nature 1983 Vol.304, P.165-167.

16. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Neither P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Cast GC. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. // J Clin Oncol. 2005 Vol.23, P.8978-91.

17. Chang JT, Morton SC, Rubenstein LZ, Mojica WA, Maglione M, Suttorp MJ, Roth EA, Shekelle PG. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. // BMJ. 2004 Vol.328, P.680.

18. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. // J Immunol. Vol.156, P.224-231.

19. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R.. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. // Nat. Med. 1996 Vol.2, P.52-58.

20. Garcia-Lora A, Algarra I, Collado A, Garrido F. Tumour immunology, vaccination and escape strategies. // European Journal of Immunogenetic 2003 Vol.30, P.177-83.

21. Markiewicz MA, Kast WM. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. // Cancer Invest. 2004 Vol.22, P.417-34.

22. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. // Clin Cancer Res. 2006 Vol.12, .2342-2345.

23. Gallimore A, Hengartner H, Zinkernagel R. Hierarchies of antigen-specific cytotoxic T-cell responses. // Rev Immunol. 1998 Vol.164, P.29-36.

24. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. // Proc. Natl. Acad. Sci. USA 1996 Vol 93, P.9730-9735.

25. Zinkernagel RM, Hengartner H. On immunity against infections and vaccines: credo 2004. // Scand J Immunol. 2004 Vol.60, P.9-13.

26. Berd, D., Maguire, H.C.J., McCue, P., Mastrangelo, M.J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. // Clin. Oncol. 1990 Vol.8, P.1858-1867.

27. Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, floors are only L, N. Dimasi Human natural killer cell receptors: insights into their molecular function and structure. // J Cell Mol Med. 2003 Vol.7, P.376-87.

28. Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. // Hum Gene Ther. 1998 Vol.9, P.835-843.

29. Hombach A, Kohler H, Rappl G, Abken H. Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. // J Immunol. 2006 Oct Vol.177, P.5668-75.

30. Marsman M, Jordens I, Griekspoor A, Neefjes J. Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis. // Adv Cancer Res. 2005 Vol.93 P.129-58.

31. Logunova NN, Viret C, Pobezinsky LA, Miller SA, Kazansky DB, Sundberg JP, Chervonsky AV. Restricted MHC-peptide repertoire predisposes to autoimmunity. // J Exp Med. 2005 Vol.202, P.73-84.

32. Wright SC, Bonavida B. YAC-1 variant clones selected for resistance to natural killer cytotoxic factors are also resistant to natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci USA. 1983 Vol.80, P.1688-92.

33. Peter I, Mezzacasa A, LeDonne P, Dummer R, Hemmi S. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. // Melanoma Res. 2001 Vol.11, P.21-30.

<> The line of human melanoma cells ILG, secreting recombinant granulocyte-macrophage colony-stimulating factor human encoded by the DNA sequence SEQ ID NO:1, deposited in the special collection of cell cultures vertebrate Russian cell culture collection under the number RCCC (P) D.



 

Same patents:

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line 31G has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The 31G cell line is deposited in the Special collection of cell cultures of vertebrates of the Russian collection of cell cultures under number RKKK (P) 698D. All cells of the 31G line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line IG has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The IG cell line is deposited in the Special collection of cell cultures of cage vertebrates of the Russian collection of cell cultures under number RKKK (P) 700D. All cells of the IG line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line 26G has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The 26G cell line is deposited in the Special collection of cell cultures of cage vertebrates of the Russian collection of cell cultures under number RKKK (P) 701D. All cells of the 26G line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line PG has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The PG cell line is deposited in the Special collection of cell cultures of cage vertebrates of the Russian collection of cell cultures under number RKKK (P) 702D. All cells of the PG line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology and specifically to media for growing cultures of autologous lymphocytes and can be used for treating and preventing pyoinflammatory complications in patients. The medium for growing a culture of autologous lymphocytes based on the RPMI - 1640 (Roswell Park Memorial Institute) culture medium contains 10% phytohemagglutinin solution and blood plasma, obtained from any central or peripheral vein of a patient, for whom the culture of autologous lymphocytes is grown, with the following ratio of components in vol. %: blood plasma of the patient - 0.75-1.2; 10% phytohemagglutinin solution in the RPMI-1640 culture medium - 0.008-0.013; RPMI - 1640 culture medium - the rest up to 100%.

EFFECT: invention provides high reliability of preventing allergic reactions of the body of the patient, increases content of lymphocytes in the culture of autologous lymphocytes, prevents occurrence of foreign proteins and provides the required sterility due to prevention of bacteria germination.

3 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: method for combined immunobiological analysis of cells using a biochip involves incubation of the biochip which contains immobilised antibodies, with suspension of cells, washing the biochip from non-bonded cells, determination of coexpression of antigens on the bonded cells. The obtained result is assessed by determining presence of bonded cells in the region of the stain of the biochip and bonding density of cells and interpretation of the obtained result. Coexpression of antigens on cells bonded to the biochip is determined by carrying out one or more immunocytochemical reactions. When reading out the result, morphological analysis of cells bonded to the biochip is also carried out and presence and character of colouring of cells and their components with the reaction product are determined.

EFFECT: use of the disclosed method provides high reliability and information content of analysis.

9 cl, 6 dwg, 2 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: method for combined immunobiological analysis of cells using a biochip involves incubation of the biochip which contains immobilised antibodies, with suspension of cells, washing the biochip from non-bonded cells, determination of coexpression of antigens on the bonded cells. The obtained result is assessed by determining presence of bonded cells in the region of the stain of the biochip and bonding density of cells and interpretation of the obtained result. Coexpression of antigens on cells bonded to the biochip is determined by carrying out one or more immunocytochemical reactions. When reading out the result, morphological analysis of cells bonded to the biochip is also carried out and presence and character of colouring of cells and their components with the reaction product are determined.

EFFECT: use of the disclosed method provides high reliability and information content of analysis.

9 cl, 6 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: embryonic tissue is flushed with enzyme solution at 25-37°C temperature. For enzyme neutralisation is used medium, made of Eagle medium with lactalbumine hydrolysate or bovine serum.

EFFECT: due to reducing of trypsin proteolitic activity and higher development temperature in stable cell cultures manufacture, yield of viable diploid cells is increased in 1,5-2 times compared to closest analogue of this invention.

7 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: method includes quail egg production, egg incubation, embryo extraction, embryolysis with trypsine solution on magnetic stirrer up to separate cells. Diet of egg-laying quails must include 3% of zeolite from Khotynez deposit of Oriol region starting from fifth day of life up to the end of egg-laying stage. Zeolite is sterilised at temperature 120° C during 1 hour before use.

EFFECT: increase of separate cells per embryo yield at 70-80%.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: new human melanoma cell line mel Ksen for antitumour vaccines manufacture is offered. Offered cell line possesses stable cultural and morphologic characteristics. Cell line is stored in Special collection of vertebrates cell cultures of Russian cell culture collection, № "РККК (П) 713Д".

EFFECT: due to melanoma marker expression invention can be used for antitumour vaccines manufacture, applied in treatment of melanoma and other malignant neoplasms.

2 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line 31G has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The 31G cell line is deposited in the Special collection of cell cultures of vertebrates of the Russian collection of cell cultures under number RKKK (P) 698D. All cells of the 31G line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line IG has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The IG cell line is deposited in the Special collection of cell cultures of cage vertebrates of the Russian collection of cell cultures under number RKKK (P) 700D. All cells of the IG line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line 26G has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The 26G cell line is deposited in the Special collection of cell cultures of cage vertebrates of the Russian collection of cell cultures under number RKKK (P) 701D. All cells of the 26G line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology, particularly to obtaining cell lines and can be used for immunotherapy and immunoprophylaxis in patients with malignant growths. The human melanoma cell line PG has stable culture, morphological and immunological characteristics and can secrete a human recombinant granulocytic-macrophagal colony-stimulating factor (GM-CSF). The PG cell line is deposited in the Special collection of cell cultures of cage vertebrates of the Russian collection of cell cultures under number RKKK (P) 702D. All cells of the PG line are characterised by stable secretion of GM-CSF stored after inactivation of cells through exposure to 100 Gy of ionising radiation which reliably prevents proliferation of the inactivated cells.

EFFECT: invention enables introduction of inactivated tumour cells into patients in order to stimulate antitumuor immunity.

FIELD: chemistry; biochemistry.

SUBSTANCE: invention pertains to biotechnology. In particular, the invention relates to an Escherichia coli BL21 (pVEGF-A165) strain and can be used to produce a vascular endothelial growth factor - GST-VEGF-A165 protein. A novel Escherichia coli BL21 (pVEGF-A165) cell strain is obtained, which is transformed by the pGEX-VEGF-A165 plasmid. This strain produces a recombinant GST-VEGF-A165 protein.

EFFECT: invention enables to obtain a Escherichia coli BL21 (pVEGF-A165) strain which is stably transformed by plasmid which codes VEGF, and which secrete this factor in extracellular space when cultured in vitro.

3 dwg, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to medical virology. The essence of the invention lies in demonstration of selective antiviral activity in netropsin derivatives: SARC-NT, Pt-bis-NT and 15Lys-bis-NT. Antiviral activity is studied on the example of anti-herpes viral and anti-orthopox viral activity in SARC-NT. A new effect was discovered in the compounds: Pt-bis-NT and 15Lys-bis-NT - anti-orthopox viral activity.

EFFECT: obtaining compounds which provide highly effective inhibition of infections caused by copox and herpes viruses; Pt-bis-NT and 15Lys-bis-NT provide highly effective inhibition of infection caused by cowpox virus; SARC-NT has considerable anti-orthopox viral activity and moderate anti-herpes viral activity; SARC-NT, Pt-bis-NT and 15Lys-bis-NT have potential for use in preparing new antiviral agents.

2 cl, 4 dwg, 1 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to contrast agents which contain a peptide vector linked with uPAR, marked with a visualising group.

EFFECT: obtaining a contrast agent for detecting urokinase plasminogen activator receptor.

6 cl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and deals with mutant virus of bull diarrhea. Essence of invention includes virus of bull diarrhea, containing at least one amino acid mutation of helicase domaine, where mutation in domain NS3 results in loss of recognition by monoclonal antibody, generated against wild type of NS3, but were virus RNA replication and generation of infectious virus are preserved. Second version includes virus of bull diarrhea containing at least one mutation in helicase domain, where mutation is in helicase domain in IGR loop and/or in KHR loop and/or in SES loop.

EFFECT: advantage of invention lies in obtaining mutant virus of bull diarrhea, where virus RNA replication and generation of infectious virus are preserved.

21 cl, 10 ex, 7 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to cell biology, molecular biology, cancer biology and medicine and represents a pharmaceutical composition for targeting to the cells bearing BLyS receptor, containing an effective amount of fused protein consisting of BLyS polypeptide fused with cytotoxic polypeptide where said cytotoxic polypeptide is located on the N-end of fused protein, and BLyS polypeptide is located on the S-end of fused protein, and a pharmaceutically acceptable carrier.

EFFECT: invention provides treatment and prevention of B-cell proliferative disorder.

11 cl, 13 ex, 4 tbl, 20 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to cell biology, molecular biology, cancer biology and medicine and represents a pharmaceutical composition for targeting to the cells bearing BLyS receptor, containing an effective amount of fused protein consisting of BLyS polypeptide fused with cytotoxic polypeptide where said cytotoxic polypeptide is located on the N-end of fused protein, and BLyS polypeptide is located on the S-end of fused protein, and a pharmaceutically acceptable carrier.

EFFECT: invention provides treatment and prevention of B-cell proliferative disorder.

11 cl, 13 ex, 4 tbl, 20 dwg

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention relates to (i) essentially crystalline melagatran in the form of hydrate, which is characterized by x-ray diffraction pattern on powder having crystalline peaks with following d values: 21.1, 10.5, 7.6, 7,0, 6.7, 6.4, 6.2, 5.7, 5.4, 5.3, 5.22, 5,19, 5.07, 4.90, 4.75, 4,68, 4.35, 4.19, 4.00, 3.94, 3.85, 3.81, 3.73, 3.70, 3.63, 3.52, 3.39, 3.27, 3,23, 3.12, 3.09, 3.06, 2.75, 2.38, and 2.35 Å and/or water content 4.3%; and (ii) essentially crystalline melagatran in the form of anhydrate, which is characterized by x-ray diffraction pattern on powder having crystalline peaks with following d values: 17.8, 8.9, 8.1, 7.5, 6.9, 6.3, 5.9, 5.6, 5.5, 5.4, 5.3, 5.2, 5.0, 4.71, 4.43, 4.38, 4.33, 4.14, 4.12, 4.05, 3.91, 3.73, 3.61, 3.58, 3.56, 3.47, 3.40, 3.36, 3,28, 3.24, 3.17, 3.09, 3.01, 2.96, 2.83, 2.54, 2.49, 2.41, 2.38, and 2.35 Å. Invention also relates to a method for preparation of indicated form, a method for interconversion of anhydrite form, to use of indicated compounds as pharmaceutical agent, and to preparation of drugs. Pharmaceutical preparation is suitable for treatment of condition, in case of which inhibition of thrombin is needed or desirable. Invention provides a method for treatment of such condition.

EFFECT: increased chemical stability and solid state stability as compared to amorphous forms of melagatran.

14 cl, 4 dwg, 3 tbl, 9 ex

Up!